Dr. James M. Croop

Pediatric Hematology Oncology
705 Riley Hospital Dr, Roc 4340, 
Indianapolis, IN 
705 Riley Hospital Dr, Roc 4340, 
Indianapolis, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

James Croop is a Pediatric Hematologist Oncology provider in Indianapolis, Indiana. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Pineocytoma, Osteosarcoma, and Ewing Sarcoma.

His clinical research consists of co-authoring 13 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in IN
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

705 Riley Hospital Dr, Roc 4340, Indianapolis, IN 46202

Additional Areas of Focus

Dr. Croop has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: April 13, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, Cytarabine, Fludarabine Phosphate, Methotrexate, Pevonedistat, Hydrocortisone
Study Phase: Phase 1
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Other
Study Drug: Selinexor
Study Phase: Phase 1
A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan
A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Other
Study Phase: Phase 1
A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: October 22, 2024
Intervention Type: Drug
Study Drugs: Irinotecan, Pevonedistat, Temozolomide
Study Phase: Phase 1
A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults With Recurrent or Relapsed Solid Tumors
A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults With Recurrent or Relapsed Solid Tumors
Enrollment Status: Completed
Publish Date: July 15, 2024
Intervention Type: Biological, Other
Study Drug: Pepinemab
Study Phase: Phase 1/Phase 2
A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas
A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas
Enrollment Status: Completed
Publish Date: January 31, 2024
Intervention Type: Drug, Other, Radiation
Study Drug: Adavosertib
Study Phase: Phase 1
A Phase 1 Study of Crizotinib in Combination With Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
A Phase 1 Study of Crizotinib in Combination With Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Enrollment Status: Completed
Publish Date: January 05, 2024
Intervention Type: Drug, Other
Study Phase: Phase 1
A Phase 1 Study of LY2606368 (Prexasertib Mesylate Monohydrate) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors
A Phase 1 Study of LY2606368 (Prexasertib Mesylate Monohydrate) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: December 20, 2023
Intervention Type: Other, Drug
Study Phase: Phase 1
A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug, Other
Study Drug: Entinostat
Study Phase: Phase 1
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Biological, Other
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors
A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: September 26, 2023
Intervention Type: Drug
Study Drugs: Adavosertib, Irinotecan Hydrochloride
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: September 08, 2023
Intervention Type: Drug, Other, Biological
Study Drugs: Cytarabine, Filgrastim, Fludarabine, Liposomal Daunorubicin, Liposomal Cytarabine
Study Phase: Phase 1/Phase 2
A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors
A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: August 17, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Enrollment Status: Completed
Publish Date: March 26, 2021
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# TBD) in Children With Recurrent or Refractory Solid Tumors
A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# TBD) in Children With Recurrent or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: January 29, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 14 Less Clinical Trials

13 Total Publications

A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors.
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors.
Journal: Pediatric blood & cancer
Published: November 21, 2024
Similar Doctors
Expertise in
6
conditions
Dr. Amy D. Shapiro
Pediatric Hematology Oncology
Expertise in
6
conditions
Dr. Amy D. Shapiro
Pediatric Hematology Oncology
8326 Naab Rd, 
Indianapolis, IN 
 (9.0 miles away)
317-871-0000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amy Shapiro is a Pediatric Hematologist Oncology provider in Indianapolis, Indiana. Dr. Shapiro is highly rated in 6 conditions, according to our data. Her top areas of expertise are Blood Clots, Hemophilia A, Hemophilia B, and Ligneous Conjunctivitis.

Expertise in
7
conditions
Dr. Steven D. Rhodes
Pediatric Hematology Oncology
Expertise in
7
conditions
Dr. Steven D. Rhodes
Pediatric Hematology Oncology
705 Riley Hospital Dr, Roc 4340, 
Indianapolis, IN 
 (0.1 miles away)
317-944-2143
Languages Spoken:
English
See accepted insurances

Steven Rhodes is a Pediatric Hematologist Oncology provider in Indianapolis, Indiana. Dr. Rhodes is highly rated in 7 conditions, according to our data. His top areas of expertise are Neurofibromatosis, Neurofibromatosis Type 1 (NF1), Optic Glioma, and Malignant Peripheral Nerve Sheath Tumor.

Expertise in
9
conditions
Dr. Seethal A. Jacob
Pediatric Hematology Oncology
Expertise in
9
conditions
Dr. Seethal A. Jacob
Pediatric Hematology Oncology

University Pediatric Associates Inc

705 Riley Hospital Dr, 
Indianapolis, IN 
 (0.1 miles away)
317-944-5000
Experience:
16+ years
Languages Spoken:
English
See accepted insurances

Seethal Jacob is a Pediatric Hematologist Oncology provider in Indianapolis, Indiana. Dr. Jacob has been practicing medicine for over 16 years is highly rated in 9 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Hemolytic Anemia, and Pacemaker Implantation.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Croop's expertise for a condition
ConditionClose
        View All 23 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile